$ZTS (Zoetis Inc.)

$ZTS {{ '2016-08-03T14:00:38+0000' | timeago}} • Webcast

$ZTS said in 2Q16, China was up 49% operationally. In Brazil, cattle and companion animal sales were strong but partially offset by weakness in poultry. Brazil grew 6% operationally in 2Q16. Australia posted a solid 10% operational growth. In the UK, the company saw sales decline 21% operationally.

$ZTS {{ '2017-12-12T13:32:16+0000' | timeago}} • Announcement

$ZTS BoD declared 1Q18 dividend of $0.126 per share of the company’s common stock, an increase of 20% from the quarterly dividend rate paid in 2017. The dividend is to be paid on Thursday, March 1, 2018, to holders of record on Friday, January 19, 2018.

$ZTS {{ '2017-11-07T19:49:47+0000' | timeago}} • Infographic

$ZTS Zoetis Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$ZTS {{ '2017-10-06T11:07:34+0000' | timeago}} • Announcement

$ZTS BoD declared a 4Q17 dividend payable to holders of the company’s common stock of $0.105 per share. The dividend is payable on Friday, Dec. 1, 2017, to holders of record on Nov. 9, 2017.

$ZTS {{ '2017-08-08T18:36:56+0000' | timeago}} • Webcast

$ZTS stated that its key markets in Europe performed well in 2Q17, the UK and Germany leading with 12% and 8% operational growth respectively. The growth was driven primarily by strong Apoquel sales.

$ZTS {{ '2017-08-08T15:06:46+0000' | timeago}} • Infographic

$ZTS Zoetis, Inc Segment Revenue Comparison Q2 2017

$ZTS {{ '2017-08-08T11:57:37+0000' | timeago}} • Announcement

$ZTS revenue in the US segment was $623MM in 2Q17, an increase of 5%, as sales of companion animal products grew 7%. Meanwhile, in the International segment, a 12% growth in companion animal products lifted revenue 5% to $634MM.

$ZTS {{ '2017-08-08T11:44:20+0000' | timeago}} • Announcement

$ZTS updated its guidance for FY17, and now expects revenue between $5.15-5.25Bil. While GAAP EPS is anticipated between $2.12 and $2.21, adjusted diluted EPS is predicted to be $2.30-2.37.

$ZTS {{ '2017-08-08T11:39:52+0000' | timeago}} • Announcement

Animal health company $ZTS reported 2Q17 revenue of $1.3Bil, up 5%, helped by higher sales in companion animal products in both the US and International segments. Net income grew 10% to $247MM, or $0.50 per share. On a adjusted basis, $ZTS earned $261MM, or $0.53 per share during the quarter.

$ZTS {{ '2017-08-04T18:38:36+0000' | timeago}} • Announcement

$ZTS, an animal health company, has appointed Linda Rhodes to its BoD, effective Aug. 3, 2017. She will serve on the Quality and Innovation Committee of the Board.

$ZTS {{ '2017-07-31T15:45:00+0000' | timeago}} • Announcement

$ZTS has completed the acquisition of $NVET, a biologic therapeutics company. Under the terms of the transaction, $NVET shareholders will receive $6.72 per share representing an aggregate equity valuation of approx. $85MM.

$ZTS {{ '2017-06-16T17:01:44+0000' | timeago}} • Announcement

Nexvet Biopharma, $ZTS, and Zoetis Belgium jointly dispatched a letter to the holders of convertible securities of Nexvet in accordance with Rule 15 of the Irish Takeover Rules to provide information regarding how the Acquisition of Nexvet by $ZTS will affect such securities.

$ZTS {{ '2017-05-11T20:52:27+0000' | timeago}} • Announcement

$ZTS BoD declared 3Q17 dividend of $0.105 per share, payable to holders of the company’s common stock. The dividend is payable on Sept. 1, 2017, to holders of record on June 15, 2017.

$ZTS {{ '2017-05-11T11:47:10+0000' | timeago}} • Announcement

$ZTS announced a plan to expand capacity at its Global Manufacturing and Supply facility in Kalamazoo, Mich. $ZTS will install two new production lines and related operations to manufacture oral tablet and chewable medicines for companion animals. $ZTS expects to add up to 45 manufacturing positions in the next 3 years.

$ZTS {{ '2017-05-04T12:18:44+0000' | timeago}} • Announcement

In 1Q17, $ZTS' revenue in the US segment was $605MM, a growth of 4% YoY. Meanwhile, revenue in the International segment rose 8% on a reported basis and 9% operationally to $615MM.

$ZTS {{ '2017-05-04T12:14:52+0000' | timeago}} • Announcement

$ZTS reaffirmed its guidance for FY17. Revenue is expected between $5.1Bil and $5.225Bil, while EPS is estimated between $2.08 and $2.20. Adjusted EPS is predicted in the range of $2.26-2.36.

$ZTS {{ '2017-05-04T12:11:09+0000' | timeago}} • Announcement

Animal health company $ZTS posted 17% improvement in net income in 1Q17, helped by a 6% hike in revenue to $1.2Bil. Net income was $238MM, or $0.48 per share, compared to $204MM, or $0.41 per share in the year-over period. On an adjusted basis, $ZTS earned $0.53 per share.

$ZTS {{ '2017-04-27T13:42:42+0000' | timeago}} • Announcement

$ZTS said the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab). Cytopoint is indicated to treat the clinical signs, including itching and inflammation, associated with atopic dermatitis in dogs of any age weighing 3 kilograms or more.

$ZTS {{ '2017-04-13T14:44:27+0000' | timeago}} • Announcement

$ZTS will acquire $NVET for $6.72 in cash per ordinary share, which values the entire issued and to be issued ordinary share capital of Nexvet at approx $85MM. This per share purchase price represents a 66% premium over Nexvet’s April 12, 2017 closing price. The acquisition will be completed in H2 of 2017.

$ZTS {{ '2017-02-16T14:30:06+0000' | timeago}} • Announcement

$ZTS said the European Commission has granted the company a license for Stronghold Plus (selamectin/sarolaner), a topical combination of parasiticides that treats ticks, fleas, ear mites, lice and gastrointestinal nematodes and prevents heartworm disease in cats.

$ZTS {{ '2017-02-16T14:23:52+0000' | timeago}} • Webcast

$ZTS expects to exceed its target of $300MM in savings for 2017. Also for the year, the company has planned to initiate direct-to-consumer marketing and advertising campaigns in the U.S. for its animal products.

Recent Transcripts

ICCC (ImmuCell Corp.)
Monday, November 13 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
PRGO (Perrigo Company Public Limited Company)
Thursday, November 9 2017 - 1:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
HSKA (Heska Corporation)
Thursday, November 2 2017 - 3:00pm
ZTS (Zoetis Inc.)
Thursday, November 2 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
PFE (Pfizer Inc.)
Tuesday, October 31 2017 - 2:00pm
ADM (Archer-Daniels-Midland Company)
Tuesday, October 31 2017 - 1:00pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
MRK (Merck & Co. Inc.)
Friday, October 27 2017 - 12:00pm
ABAX (Abaxis, Inc.)
Tuesday, October 24 2017 - 8:15pm
NVS (Novartis AG)
Tuesday, October 24 2017 - 12:00pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm

AlphaGraphics you may like